Trial Profile
A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2021
Price :
$35
*
At a glance
- Drugs Baloxavir-marboxil (Primary) ; Favipiravir (Primary) ; Antivirals
- Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- 18 Jan 2021 Status has been changed to completed.
- 18 Jan 2021 Results evaluating the clinical outcomes and plasma concentrations of baloxavir acid and favipiravir in COVID-19 patients, published in the European Journal of Pharmaceutical Sciences
- 23 Jun 2020 New trial record